Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2

Conditions

Leukemia, Myeloid, Acute 3Myeloproliferative Disorders 2Myelodysplastic Syndromes 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 154pembrolizumab 152Carboplatin 115Biopsy 110Cyclophosphamide 100Cisplatin 88Paclitaxel 80Gemcitabine 72Bevacizumab 70fludarabine 61Nivolumab 60Radiotherapy 52Fluorouracil 52Capecitabine 49Dexamethasone 48Pemetrexed 46Rituximab 44Oxaliplatin 44Docetaxel 44Leucovorin 43atezolizumab 42Doxorubicin 42venetoclax 39durvalumab 39Standard of Care 34Prednisone 34Temozolomide 33Radiation 33Cetuximab 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Liposomes × 30 days × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03629171 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
52 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡